Evvy Unveils Innovative Fertility Test Through Vaginal Microbiome Analysis
United States, Friday, 21 March 2025.
Evvy’s new vaginal microbiome test introduces groundbreaking insights into fertility, often overlooked in reproductive health, offering personalized care options for those seeking conception solutions starting at €129.
Revolutionizing Fertility Testing
On March 18, 2025, Evvy introduced its groundbreaking Fertility Insights technology, utilizing metagenomic next-generation sequencing (mNGS) to provide the first validated at-home vaginal microbiome fertility test [1]. The innovation addresses a critical gap in reproductive healthcare, particularly relevant given that one-third of infertility cases are currently classified as ‘unexplained’ [2]. The test comprehensively analyzes over 700 bacteria and fungi species, along with four fertility-related microbiome markers [3].
Scientific Basis and Key Features
The test’s significance lies in its ability to detect crucial microbiome patterns linked to fertility outcomes. Research has demonstrated that vaginal microbial imbalances can significantly impact fertility, with women experiencing infertility being 3.3 times more likely to have bacterial vaginosis compared to those without fertility issues [4]. The platform offers three key metrics: a Protective Score measuring beneficial bacteria levels, a Microbiome Diversity Score correlating with IVF outcomes, and identification of Fertility Disruptors including specific harmful bacteria such as Fannyhessea, Gardnerella, and Prevotella [5].
Comprehensive Health Integration
Results are delivered within a structured timeframe, with STI testing results available in 1-3 business days and complete microbiome analysis within 7-10 days [3]. The service includes personalized care protocols, prescription treatments when necessary, and one-on-one health coaching sessions [6]. For ongoing monitoring, Evvy offers a membership program allowing four tests annually, scheduled quarterly, though single-test purchases are also available [3].
Future Implications and Accessibility
Starting at $129, the test is accessible across all U.S. states except New York [3][6]. The platform aims to transform the approach to fertility treatment by enabling proactive microbiome health management before conception or IVF procedures [6]. This preventative strategy could potentially lead to significant cost savings on fertility treatments while providing clearer pathways for those seeking to conceive [6].